HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
HQY 79.56 +2.47(3.20%)
Will HQY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HQY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HQY
The Cooper Companies (COO) Q3 Earnings and Revenues Surpass Estimates
What Analyst Projections for Key Metrics Reveal About HealthEquity (HQY) Q2 Earnings
HQY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Other News for HQY
Earnings To Watch: HealthEquity Inc (HQY) Reports Q2 2025 Result
Earnings week ahead: Zscaler, DocuSign, NIO, Broadcom and more
HealthEquity: A Checkup As We Head Into Earnings
HealthEquity Secures New Credit Facility and Repays Debt
HealthEquity: Compelling Catalysts, Fairly Valued, Reiterate Buy